Pharma BD Deal Intelligence
Amgen announced acquisition of BioVex for $425M cash upfront plus up to $575M in regulatory and sales milestones, accessing OncoVEX GM-CSF Phase 3 oncolytic…
GEN reports factually that Amgen will pay '$425 million in cash and potentially another $575 million in regulatory and sales milestones,' noting Amgen is…
T-VEC received FDA approval October 2015 as Imlygic for unresectable melanoma — first oncolytic virus approved in the US — based on Phase 3 data showing…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Amgen completed acquisition of BioVex on March 4, 2011 for $425M upfront plus up to $575M in regulatory and sales milestones. Lead asset OncoVEX (later Imlygic/T-VEC) was a Phase 3 oncolytic immunotherapy for melanoma; FDA-approved 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / BioVex Group, Inc. (this deal) | 2011 | $1.0B | 37 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2011 deals · Amgen Inc. deals · Oncology deals